Get started

Stocktobuy

Why Laxmi Organics is a strong Short to Medium term BUY NSE:LXCHEM TEN POINTS 1. Laxmi Organic Industries is a specialty chemical manufacturer, focused on two key business segments - Acetyl Intermediates (AI) and Specialty Intermediates (SI)..The company is currently among the largest manufacturers of ethyl acetate in India with a market share of approximately 30% of the Indian ethyl acetate market. Laxmi Organic exports about 25% of the manufactured products. Additionally, it is the only manufacturer of diketene derivatives in India with a market share of approximately 55% of the Indian diketene derivatives market in terms of revenue in FY21 and one of the largest portfolios of diketene products 2. Stock gained 50% in one month only after listing -hitting a high of 628 and reported a significant jump in its net profit to ₹98.68 crore in the quarter ending June as compared to ₹18 crore in the corresponding quarter of the previous fiscal. Its revenue from operations also witnessed a massive jump to ₹689 crore from 354 crore in the year-ago quarter. 3. However massive rainfall in Pune factory forced the company to close one of its factories for some time during the SEP 21 quarter and Net profit tumbled from ~98 cr in SEP 21 to 10.3 cr in SEP 21 qtr. 4. Coupled with profit booking the stock tumbled to 385 levels. 5. After a 3 month consolidation the company seems to be turning around its limitations shown in the previous quarter. 6. On the positive side- India Ratings and Research (Ind-Ra) has upgraded Laxmi Organic Industries Limited’s (LOIL) Long-Term Issuer Rating to ‘IND AA-’ from ‘IND A+’. The Outlook is Stable, the ratings agency quoted 7. Despite 60% decline in SI volumes on qoq basis on account of 45 days shut down at SI Unit (Mahad) which caused heavy loss, Laxmi’s H1FY22 profits were close to FY21 performance led by rapid growth in specialty business and higher spreads in acetyl business during the first quarter and normalised acetyl spreads during the second quarter. There is a strong visibility on SI order book for H2FY22. Laxmi has acquired significant international accounts during Q2FY22, as 24% of SI sales were from exports as against 5% in Q2FY21. 8. Buying at current levels is recommended for a short to medium term target of 500-520 for the short term and 620 for the longer term. 9. Maintain stop loss around 430 10. Risk reward ratio of 1:3
NSE:LXCHEMLong
by amitach
Swing Trading Idea Ashok Leyland 1to 3 monthsSwing Trading Idea Ashok Leyland 1 to 3 months Disclaimer: These levels are purely based on Price action/demand and supply zones & and consumed only for educational purpose & should not be taken as buy/sell recommendation. I will not be responsible for any loss/profit incurred if anyone takes trades based on my views. Please consult your Financial Advisor before making any trading decision. Leave a comment that is helpful or encouraging. Let's master the markets together.
NSE:ASHOKLEY
by sbkurandwad77
RIOT BUY/LONG BIG OPPORTUNITY! 15 to 97 by end 2021! TICKER CODE: RIOT Company Name: Riot Blockchain, Inc. Industry: Technology | Software - Application | USA Position Proposed: BUY Technical Analysis 1. Flag Pattern (Forming) 2. Fibonacci Retracement at 0.786 ( Silver Zone) 3. 1st Partial Take Profit will be at Fibonacci Expansion Safe Take Profit, Flagpole Length and somewhere near Key Structure Level (Very likely for price rejection/Pullback) 4. 2nd Partial Take Profit would be somewhere near the Next Key Structure Level (The Market will very likely reach this point before having a major rejection again) Entry: NOW READY (15.00-26.00) - The Market could fall below 26.00 again but very unlikely 1st Partial Take Profit: 97.00 (October - End 2021) 2nd Partial Take Profit: 2.95 (End 2021) 3rd Take Profi: 3.75 (Mid-End 2022) Note that in the Monthly chart timeframe the market is creating a large inverted Head & Shoulders, as such I will still hold some of this stock on hand. Should the market break beyond 145, the next take profit will be at roughly 200-250 price range.
NASDAQ:RIOTLong
by traderprosignals
2
BXRX long scenario 🧙Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
BLong
by unfair_advantage
MAgnaChip Nyse:MX - An interesting small-cap The stock has broken a trend line but I like its core business for the long run. I have a small position in this title. Magnachip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT , consumer, industrial and automotive applications. The Company provides a broad range of standard products to customers worldwide. Magnachip, with more than 40 years of operating history, owns a portfolio of approximately 1,200 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through Magnachip's website is not a part of, and is not incorporated into, this release: investors.magnachip.com
NYSE:MXLong
by LukkVal
K Technical Analysis 🧙Founded in 1906, Kellogg is a leading global manufacturer and marketer of cereal, cookies, crackers, and other packaged foods. Its offerings are manufactured in 21 countries and marketed in more than 180 countries. Its product mix includes well-known brands such as Special K, Frosted Flakes, Froot Loops, Rice Krispies, Pop-Tarts, Eggo, Kashi, and Morningstar Farms. The firm added the Pringles brand to its mix in 2012. Sales outside its home turf account for around 40% of Kellogg's consolidated sales base. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:KLong
by unfair_advantage
3
BUY $PFE - NRPicks Ene 17Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. Pfizer mainly sells prescription drugs and vaccines, also spends a leading amount on research and development, close to $8 billion annually. The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus. Fundamentals: - Value - P/B 3.1x VS 4.3x Industry - ROE 22% vs. 17% industry Technicians: - Price level below SMA 250-200-150 - Williams R% at -50% levels - RSI (40) Midlevel - +1% average upside during the month As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
NYSE:PFELong
by NewroadTrader
GBS Technical Analysis.Glucose Biosensor Systems (Greater China) Holdings Inc is a United States based company engaged in manufacturing of Saliva Glucose Biosensor (SGB). SGB uses saliva to measure glucose non-invasively. The Saliva Glucose Test consists of the SGB which is a single use disposable saliva biosensor and the software app that interfaces the SGB with its digital information system. If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
GLong
by unfair_advantage
1